Thiel's Breakout Labs backs 3 biotech upstarts; Hedge fund manager going after Acorda;

@FierceBiotech: Sanofi embarks on an $845M gene therapy R&D odyssey with Voyager. Report | Follow @FierceBiotech

@JohnCFierce: I think it's smart of Sanofi to buy into new tech and let the partner lead on innovation. Good model for pharma, which is bad at innovation. | Follow @JohnCFierce

@DamianFierce: In which the commissioner of the FDA reminds Americans that we have two very effective vaccines for measles. More | Follow @DamianFierce

> FaceBook-famous Peter Thiel has selected the next three biotechs to get seed funding from his Breakout Labs. They are Boston-based Neumitra, which is "developing embedded biomodules and an associated bioinformatics platform to accurately measure and respond to physiological stress in real time"; Danville, CA-based Ion Dx, advancing bench-top instrumentation to measure proteins in biological samples; and Menlo Park, CA-based E3XBio, which "has created a streamlined drug-discovery platform based on the active properties of 'undruggable' targets." Release

> Business Insider reports that hedge fund manager Kyle Bass is launching an attack on Acorda's ($ACOR) patent for its flagship drug Ampyra. Story

Medical Device News

@FierceMedDev: ICYMI yesterday: Biosensors Japan's PhIII trial of drug eluting has enrolled patients. Report | Follow @FierceMedDev

@VarunSaxena2: Endoscopes linked to spread of deadly drug-resistant bacteria in hospitals. Story | Follow @VarunSaxena2

@EmilyWFierce: Patient groups still think ViiV is tops, with Novo and AbbVie close behind. FiercePharmaMarketing article | Follow @EmilyWFierce

> Investors set sail toward China's rapidly growing device market. Story

> Welch Allyn partners with Spok to provide mobile alerts for its vital signs monitors. Article

Pharma News

@FiercePharma: GSK strengthens early stage vaccine pipeline with acquisition of GlycoVaxyn AG. Release | Follow @FiercePharma

@CarlyHFierce: ICYMI: FDA puts off Mylan's Nexium generic, giving Teva's version free rein. Story | Follow @CarlyHFierce

> Glaxo's new meds are finally grabbing market share--but can they keep it up? Article

> Pfizer CEO thinks buys and swaps, with an eye toward future breakup. Story

> Can Valeant turn Dendreon's flailing Provenge into a viable cancer competitor? More

Drug Delivery News

> SteadyMed seeks $55M IPO to fund its drug delivery device, looks to upend United Therapeutics' Remodulin. Article

> The future: Biodegradable surgical tools to deliver drugs to remote parts of the body? Item

> UNC team uses electrical field to improve chemo delivery. Article

> Singapore team developing injectable glaucoma treatment, says noncompliance plagues eye drops. Story

> Alkermes' multiple sclerosis prodrug looks good in Phase I, has Biogen Idec's Tecfidera in its sights. More

Diagnostics News

> Trovagene aims to raise $20M follow-on for urine-based cancer diagnostic. Report

> Japan's Quantum Biosystems raises $20M for next-gen DNA sequencer. News

> Roche scoops up Signature Diagnostics to gain ground in next-generation sequencing. Story

> Biocartis develops rapid Ebola triage test with Janssen Diagnostics. Item

> Myriad calls it quits on BRCA patent battle against Quest. Article

Pharma Marketing News

> Can Valeant transform Dendreon's ailing Provenge into a viable cancer competitor? Item

> Shire volleys with tennis star Seles to promote Vyvanse for binge eating. Report

> Patient groups still think ViiV is tops, with Novo and AbbVie close behind. Story

> Merck touches off Canadian controversy with Januvia doctor survey. Article

> Once again, Big Pharma's bad rep goes viral. Fair or not fair? More

Suggested Articles

EQRx is adding a pair of PD-1/PD-L1 meds to its pipeline through a deal with CStone worth $150 million upfront but could net the latter $1.15 billion.

All eyes are on Pfizer’s COVID-19 vaccine work, but the Big Pharma has today quietly culled two midstage trials and one phase 1 test.

All subjects had lower extremity weakness after receiving antisense oligonucleotide GTX-102, leading Ultragenyx to pause the study.